Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: J Neuroimmune Pharmacol. 2016 Mar 18;11(2):316–331. doi: 10.1007/s11481-016-9664-y

Figure 5. WIN55,212-2 significantly decreased the frequency but not amplitude of mIPSCs in PFC pyramidal neurons, which was blocked by rimonabant but not AM630.

Figure 5

(a) WIN55,212-2 (1 μM) or WIN + Tat (10 nM) had no significant effect on the mean frequency and amplitude of sIPSCs (n = 7). (b) Representative traces show mIPSCs before WIN55,212-2 (1 μM), after WIN55,212-2, and after WIN + Tat (10 nM) application. (c, c′, c″) Effects of WIN55,212-2 (1 μM) and Tat (10 nM) on the mean frequency of mIPSCs. WIN55,212-2 significantly decreased the mean frequency of mIPSCs with WIN + Tat not changing the WIN55,212-2-induced decrease in frequency of mIPSCs (n = 7, c). Pretreatment with rimonabant (1 μM) blocked the WIN55,212-2-induced decrease in the mean frequency of mIPSCs (n = 9, c′). Pretreatment with AM630 (1 μM) did not prevent the WIN55,212-2- and WIN + Tat-induced decreases in the mean frequency of mIPSCs (n = 8, c″). (d, d′, d″) Effects of WIN55,212-2 (1 μM) and Tat (10 nM) on the mean amplitude of mIPSCs. WIN55,212-2 blocked the Tat-induced decrease in mean amplitude of mIPSCs (n = 7, d). No significant effects were noted when pretreating PFC slices with rimonabant (1 μM, n = 9, d′). Pretreatment with AM630 (1 μM) significantly decreased the mean amplitude of mIPSCs for WIN55,212-2 and WIN + Tat compared to control (n = 8, d″). Data are mean ± SEM. Significance was assessed by paired Student t-tests. *p < 0.05 vs. Control, #p < 0.05 vs. AM (1 μM). WIN: WIN55,212-2; Rim: rimonabant; AM: AM630.